Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Major Depressive Disorder: full-pipeline trial registry
109 of 283 indexed Major Depressive Disorder trials are currently recruiting.
Corpus placement: #33 of 28,707 conditions by registered trial count.
283 US clinical trials · 109 currently recruiting · #33 of 28,707 conditions by registered trial count
Major Depressive Disorder: 283 US clinical trials tracked, 109 recruiting.
Major Depressive Disorder is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 109 of them currently open to new participants. 74 are in Phase 3-4 (later-stage) and 81 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 19 of these trials.
Enrollment posture brief
Registry condition major-depressive-disorder
OPEN 109 | RECR 39% | LATE 74 | EARLY 81 | RANK #33 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Anaplastic Oligodendroglioma (38% recruiting · 13 trials)
Major Depressive Disorder lists 109 open slots (39% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Major Depressive Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Major Depressive Disorder recruits in line with its size-band peers.
109 of 283 indexed trials (38.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Major Depressive Disorder trials is spread across many organizations.
Massachusetts General Hospital accounts for 19 of 283 trials (6.7%). 118 distinct sponsors appear on at least one study for this condition label.
-
Typical Major Depressive Disorder enrolment sits around 81 participants.
Median target enrolment is 81 among the 283 trials that report a genuine target (sentinel values excluded). 145 of those (51.2%) plan for fewer than 100 participants.
-
Major Depressive Disorder research is mostly interventional.
258 interventional and 25 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
283 total, page 4 of 6
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
Forest Laboratories
NCT00969709
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)
Sanofi
NCT00385307
Combining Medications to Enhance Depression Outcomes
National Institute of Mental Health (NIMH)
NCT00590863
Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
Forest Laboratories
NCT00384436
TC-5214 as add-on the Treatment of Major Depressive Disorder
Targacept
NCT00692445
Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
Pamlab
NCT01369030
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
Forest Laboratories
NCT00109044
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
Forest Laboratories
NCT01878292
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
Forest Laboratories
NCT01473394
Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder
Allergan
NCT03569475
Can Genetics Predict Treatment Response to a Computerized Self-help Program for Depression?
University of Texas at Austin
NCT01818453
A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT00073203
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies
NCT04985942
Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)
Forest Laboratories
NCT00683592
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
Sanofi
NCT00252330
A Study for Participants With Major Depression
Eli Lilly and Company
NCT00420004
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
Sanofi
NCT00252356
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
Massachusetts General Hospital
NCT00633399
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Pfizer
NCT01371734
A Study of Aripiprazole in Patients With Major Depressive Disorder
Otsuka Pharmaceutical Development & Commercialization
NCT00105196
Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD
Senseye
NCT05717439
NeuroStar TMS Therapy System: Utilization and Outcomes
Neuronetics
NCT01114477
Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD
Genomind
NCT02634177
Phase 2b Study of ALTO-100 in MDD
Alto Neuroscience
NCT05712187
A Study of Pregnant and Postpartum Women With and Without Mood Disorders
Johns Hopkins University
NCT03615794
Comparing Group Therapies for Veterans With Depression and PTSD
VA Office of Research and Development
NCT03979040
ALTO-100 in MDD and/or PTSD
Alto Neuroscience
NCT05117632
A Comparison of Cognitive and Dynamic Therapy for Depression in Community Settings
University of Pennsylvania
NCT01207271
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
Relmada Therapeutics
NCT05081167
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Relmada Therapeutics
NCT04688164
Study of Adolescence and Depression
Kaiser Permanente
NCT00523081
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Wave Neuroscience
NCT01370733
Examination of Glutamate and mGluR5 in Psychiatric Disorders
Yale University
NCT02727972
Empower: tDCS for Major Depressive Disorder at Home
Flow Neuroscience AB
NCT05202119
Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness
Dartmouth-Hitchcock Medical Center
NCT02421965
Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics
New York State Psychiatric Institute
NCT00742573
Brain Regulation of Emotions in People With Depression and Anhedonia
National Institute of Mental Health (NIMH)
NCT00059579
African American Depression Intervention Trial (AADI)
University of Wisconsin, Madison
NCT01342536
AZD6765 Severe Major Depressive Disorder (MDD) IV
AstraZeneca
NCT00781742
Depression and Dopamine Transporter Function Study Using C-11 Altropane
Mclean Hospital
NCT01701141
Effects of Early Abuse on Adult Intimate Relationships
University of Texas at Austin
NCT01803802
ALTO-300 in Depression (ALTO-300-004)
Alto Neuroscience
NCT05157945
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Alkermes
NCT01500200
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
BlackThorn Therapeutics
NCT01724112
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
Mclean Hospital
NCT05537584
Contingency Management of Alcohol Abuse in the Severely Mentally ILL
University of Washington
NCT01567943
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
Takeda
NCT02972632
Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression
Eli Lilly and Company
NCT00042575
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Massachusetts General Hospital
NCT00555997
A Study of Intermittent Doses of CERC-301 in MDD
Avalo Therapeutics
NCT02459236
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 57 |
| Phase 3 | 45 |
| Phase 4 | 29 |
Top Sponsors
Named interventions
Most-linked intervention names on Major Depressive Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Major Depressive Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Major Depressive Disorder page
283 registered trials, 109 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 109 Major Depressive Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Major Depressive Disorder trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Major Depressive Disorder condition card totals 283 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.